other countries for all adults 65 years of age and older as well as younger adults with certain chronic conditions [1] . Like PPSV23, the 13-valent pneumococcal conjugate vaccine (PCV13) has been approved by the US Food and Drug Administration and selected other regulators for vaccination of adults aged 50 years and older. The basis for licensure for the adult indication for PCV13 relies on its noninferior immunogenicity for matched serotypes, when compared to adult responses to PPSV23 [2] . There is no known correlate of protection, or antibody level at which a clinical effect would be expected, for pneumococcal disease in adults, hence it is not possible to translate such immunogenicity measures into expected efficacy or effectiveness measure [1] .
In February 2012, the US ACIP chose to continue its 1997 recommendation for routine adult use of PPSV23 rather than recommend routine use of PCV13, until more data become available related to clinical effectiveness of PCV13 and the magnitude of indirect reduction in adult disease due to routine vaccination of children with PCV13 [2, 3] . In June 2012, the ACIP voted to recommend a sequential regimen of PCV13 and PPSV23 for certain high-risk adults with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal leaks, or cochlear implants. These recommendations were published in October 2012 [1] .
The ACIP decision-making process included assessments of cost-effectiveness data comparing PCV13 and PPSV23 in adults. Such cost-effectiveness models require explicit assumptions of effectiveness to be specified;
however, there are neither any published clinical-outcomes data that compare the two vaccines in adult populations, nor are there any published trials evaluating the efficacy or effectiveness of PCV13 in healthy adults against either invasive pneumococcal disease (IPD) or non-bacteremic pneumococcal pneumonia (NBPP). Several clinical trials and observational studies have evaluated the efficacy and effectiveness of PPSV23 in preventing both invasive and non-invasive diseases [4] [5] [6] , and there are several metaanalyses of these data [7] [8] [9] . The data are consistent regarding PPSV23 effectiveness for invasive disease; however, there are inconsistent meta-analysis results and interpretations regarding PPSV23 effectiveness for preventing non-invasive disease (i.e., NBPP) [7, 8] .
Recently published economic analyses described the potential economic impact of different adult pneumococcal vaccine regimens. A paper by Smith et al. [9] modeled the potential economic impact of various vaccination strategies on pneumococcal disease among adults 50 years of age and older. This analysis compared PCV13 to PPSV23, concluding that routine use of PCV13 at ages 50 and 65 would be the most economically efficient recommendation to prevent pneumococcal disease in adults [10] . A separate paper by Weycker et al. [11] yielded similar results. Results from both models were sensitive to effectiveness assumptions for each vaccine, and both models included the assumption that PPSV23 was ineffective in the prevention of NBPP [10, 11] . However, neither of these publications explored the economic implications of the most recent ACIP sequential PCV13-PPSV23 regimen in selected high-risk populations.
Hence, the main objectives of the current analyses are to: 1. evaluate the economic implications of the 2012 ACIP recommendation compared with the 1997 ACIP recommendation; 2. examine additional relevant vaccination strategies that may be considered by decision-makers in the future, and; 3. explore the implications of various assumptions including those pertaining to vaccine effectiveness and herd protection on cost-effectiveness conclusions.
METHODS
All appendices mentioned below can be found in the supplementary material published alongside the online version of this article.
The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors. (Fig. 1) . Annual age-specific transition probabilities among risk groups were derived from Weycker et al. [12] (see Table S9 in Appendix 1, Distribution of Risk Groups). Vaccination strategies were assumed to reduce the baseline risk of pneumococcal disease.
Model

Vaccination Strategies
Given the need to assess two vaccines, three risk categories, and multiple vaccination age points in this economic analysis, many options were considered for defining a reasonable set of vaccination strategies that are both clinically relevant and practically implementable. For modeling purposes, this analysis is restricted to vaccination strategies for adults 50 years of age and older, for whom the 1997 ACIP recommendation (Table 1) is applicable.
Vaccination prior to the age of 50 years is not considered here, nor are adults who may have been vaccinated before the age of 50.
To explore various relevant strategies that could plausibly be implemented in the future, we defined three broad sets of strategies, totaling seven different vaccination strategies, as well as the no-vaccination strategy (which models the hypothetical disease incidence in the absence of any adult pneumococcal immunization; (strategy 3; S3) or both the comorbidities and healthy groups (strategy 4; S4). The age points for vaccination for these strategies appear in Table 2 .
The third set consists of three additional strategies that could apply if decision-makers preferred simple recommendations for the majority of individuals (healthy and immunocompetent with comorbidities) as most practical to implement (keeping vaccine choice more consistent and making age at vaccination the main patient characteristic that changes). In this set of strategies, the recommendation for the In strategy 7 (S7), the current healthy and immunocompetent with comorbidities recommendations are replaced with the PCV13-PPSV23 regimen.
Model Inputs
Disease Estimates
Estimates of annual rates of each disease outcome were based on data presented by Weycker et al. [12] (see Table S2 in Appendix 1). The rates of IPD, death and disability from IPD, hospitalized NBPP, death and disability from NBPP, and outpatient visits associated with NBPP were calculated, varying by age and risk of pneumococcal status (see Appendix 1 for description). Baseline rates of disease for the novaccination strategy were estimated using methods described previously [13] .
Proportions of the population that fall into each risk category were based on published literature (see Table S9 in Appendix 1, Distribution of Risk Groups) [12] and individuals were assumed to move from lower risk categories to higher risk categories probabilistically as they aged in the model.
The 50-year-old cohort initially included a population that was 52.3% healthy; 36.5% immunocompetent with comorbidities and 11.2% immunocompromised [12] .
Cost Estimates
Medical-care costs related to hospitalizations, outpatient visits, and deaths were included in • PPSV23 recommended for healthy adults 65 years or older, regardless of health history
• PPSV23 recommended for individuals aged 50-64 years who are immunocompetent and have certain underlying medical conditions, as well as adults with immunocompromising conditions. Re-vaccination at age 65 is also recommended for this group
ACIP recommendations
October 12, 2012-present [1] • PPSV23 recommended for healthy adults 65 years or older, regardless of health history
• PPSV23 recommended for individuals aged 50-64 years who are immunocompetent and have certain underlying medical conditions. Re-vaccination at age 65 is also recommended for this group
• PCV13 followed by PPSV23 are both recommended for adults with immunocompromising conditions, as well as functional and anatomic asplenia, cerebrospinal leaks and cochlear implants ACIP, Advisory Committee on Immunization Practices; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine Table 2 Description of pneumococcal vaccination strategies considered 
PCV13-PPSV23
the model and varied by risk status (see Table S2 in Appendix 1) [12] . Vaccine costs were based on Centers for Disease Control and Prevention reports of private-sector prices as of September 10, 2012 [14] . PPSV23 was assumed to be $57.70 per dose and PCV13 to be $120.95 per dose.
Administration cost was assumed to be $15.00
per dose for each product. Indirect costs were not included in this analysis. Costs are expressed in 2012 US dollars using medical Consumer Price Index adjustor [15] .
Utility Weights
Utility weights associated with IPD and NBPP inpatient cases, as well as baseline utilities for average-and high-risk populations were based on values described by Smith et al. [9] (see Table  S9 in Appendix 1). Utility weights associated with outpatient visits for NBPP were based on estimates related to influenza outpatient visits [10] . Duration of an event is incorporated in QALY calculation.
Vaccine Uptake
Vaccine uptake was assumed to vary depending on age and risk category and was based on contemporary US data regarding PPSV23 (see Table S9 in Appendix 1). Vaccine uptake for both PCV13 and PPSV23 was assumed to be the same for each age/risk category described. For routine age-based recommendations (at age 50 years or age 65 years), vaccine uptake was assumed to be 12.0% for healthy, 33.9% for immunocompetent with comorbidities and immunocompromised populations at age 50 years, and 60.1% for all risk categories at age 65 years.
Vaccine Effectiveness
Due to the absence of data comparing PCV13 to PPSV23 efficacy in adults, assumptions around PCV13 effectiveness against IPD and NBPP as Table 2 continued Age at vaccination (Table 3; see Appendix 2 for description of Delphi methods). PPSV23
effectiveness against IPD for the healthy and immunocompetent with comorbidities groups was based on Moberley et al. [7] and Smith et al. [9] . Effectiveness estimates described at the June 2012 ACIP meeting were used for the immunocompromised risk group [16] (Table 3; see Appendix 1 for description of the estimation of vaccine effectiveness). In the base-case analysis, PPSV23 was assumed to wane over a period of 10 years. PCV13 was assumed to be effective in healthy adults, as well as immunocompetent adults with chronic conditions and immunocompromised
populations. There are no long-term efficacy data available for PCV13 in adults, so it was assumed to wane over a period of 15 years in [17] .
Sensitivity Analyses
Given the uncertainty around several key model parameters, sensitivity analyses are critical to understanding the potential economic implications of the various vaccination strategies explored. Sensitivity analyses were conducted to examine the impact of varying assumptions related to vaccine effectiveness, impact of herd protection on disease incidence and vaccine serotype coverage. In addition, a set of scenario analyses was conducted to examine the potential cost-effectiveness of broad agebased vaccine recommendations starting at age 50.
Projected Impact of Herd Protection
To be conservative, the impact of herd protection was excluded in the base case. To assess model sensitivity to the impact of herd protection on disease incidence and serotype coverage, additional scenarios were evaluated, anticipating some future point when full reduction in adult disease due indirectly to pediatric PCV13 has been realized. Data related to reductions in IPD observed after routine pediatric use of 7-valent pneumococcal conjugate vaccine (PCV7) were applied to the modeled base-case rates of disease to generate projected disease-incidence rates after routine pediatric use of PCV13 [17] . In that future scenario, IPD and NBPP disease reductions post-PCV13 were assumed to be comparable to those seen for IPD reductions post-PCV7.
There are sufficient surveillance data to indicate that a significant herd impact post-PCV7 introduction has already occurred in the US, however, there is no consensus in the published literature regarding the potential herd impact of use of PCV7 on NBPP in adults [18, 19] . The projected herd-impact parameters varied based on certain serotype characteristics. Disease incidence associated with serotypes contained in PCV7 as well as serotypes 1 and 5
were assumed to remain at current low levels. Serotypes 1 and 5 are believed to behave differently than other serotypes in terms of carriage and transmission, so it is not clear how adult disease related to these two serotypes would be affected by pediatric use of PCV13.
The incidence of disease associated with the four other new serotypes in PCV13 was assumed to decrease in a pattern similar to the observed reductions in PCV7 types after routine pediatric vaccination began. All other serotypes (PPSV23 unique types and non-vaccine types) were assumed to increase slightly, similar to increases observed post-PCV7 implementation.
Serotype coverage for each vaccine was assumed to vary and three sets of assumptions were applied to three separate sensitivity analyses: 1. Full herd impact: PPSV23 was assumed to cover 68% of disease in adults aged 50-64 years and PCV13 20%; PPSV23 was assumed to cover 56% of disease in adults older than 65 years, and PCV13 18%; 2. Herd impact was assumed to be 50% of that projected for scenario 1;
3. Herd impact for IPD described as in scenario 1, but no herd impact assumed for NBPP. In this scenario NBPP rates of disease and serotype distributions were equivalent to base-case assumptions.
Waning of Effectiveness
Recent studies demonstrate that PPSV23 induces antibody responses that remain above the levels of unvaccinated adults for 5-10 years or more [20] . Little long-term effectiveness data are available for PCV13 in adults. To understand the impact of waning assumptions of costeffectiveness results, three sensitivity analyses were generated: 1. PCV13 and PPSV23 were assumed to have equivalent waning rates of 10 or 15 years; 
RESULTS
Projected Pneumococcal Disease Events
Total projected IPD cases (survived), NBPP hospitalizations (survived), disabled cases (survived), outpatient visits, and deaths for the no-vaccination strategy, along with the projected events averted for the seven vaccination strategies were generated ( Table 4 ).
The model projects that for a single cohort of 100,000 adults starting at age 50 years, in the absence of pneumococcal vaccination, there (Table 4) .
Economic Evaluation
For objective 1, three strategies were compared: no vaccination, as well as S1 (1997 ACIP recommendations) and S2 (2012 ACIP recommendations). In this first comparison, S2
is the most economically efficient strategy with an incremental cost-effectiveness ratio (ICER) of $25,841 per QALY gained, compared with no vaccination, and S1 is dominated. 
Sensitivity Analysis Results
Sensitivity analyses related to impact of disease incidence and serotype changes and due to herd protection along with changes to vaccine effectiveness assumptions are reported in Table 6 . Only non-dominated strategies are shown. Dominated strategies could have been eliminated from consideration due to strong dominance (i.e., a less expensive and more beneficial strategy available), or weak dominance (i.e., a more economically efficient strategy available). Incremental cost-effectiveness ratios are compared as follows: rank 1 vs. no vaccination, rank 2 vs. rank 1, and rank 3 vs. rank 2. Several sensitivity analyses had more than three non-dominated strategies, but only the top three strategies are shown. Full herd impact projections based on changes in adult IPD observed post-introduction of 7-valent pneumococcal conjugate vaccine [17] ICER, incremental cost-effectiveness ratio; IPD, invasive pneumococcal disease; NBPP, non-bacteremic pneumococcal pneumonia; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; US$, United States dollars
Herd Protection
The potential impact on cost-effectiveness results due to projected changes in disease incidence for both IPD and NBPP along with serotype coverage for each vaccine was examined using three sensitivity analysis scenarios. For the first scenario, simulating the impact of full herd protection, the three most economically efficient strategies were S1 ($51,000 vs. no vaccination), followed by S2
($77,000 vs. S1) and S5 ($103,000 vs. S2). If 50% less herd impact were to occur, S5 would be the most economically efficient ($36,000 vs. no vaccination), followed by S7. When it was assumed that herd protection did not impact incidence of NBPP, S1 was found to be the most economically efficient strategy followed by S5 and S3 (Table 6 ).
PPSV23 Effectiveness Against NBPP
When PPSV23 vaccine effectiveness for preventing NBPP was assumed to be 10%
greater than base case in the first year postvaccination, the order of preferred vaccination strategies in the economic analysis were maintained but with ICERs reduced. Reductions in PPSV23 effectiveness (from 10% to 100% less relative to first year postvaccination in the base case) did not affect S5 to be the most economically efficient strategy. But the economic efficiency for S6 improved substantially, with ICER reducing from $150,000 to $39,000 against S5. When PPSV23 effectiveness against NBPP was decreased by 100% (i.e., assumed to be 0) versus base case, S5
and S6 became similarly efficient (ICER $35,000 and $36,000, respectively, per QALY gained vs.
no vaccination).
Waning of Effectiveness
Vaccine-waning patterns were found to impact cost-effectiveness results in the sensitivity analyses. When the two vaccines were assumed to have equivalent waning periods of 10 years, the most economically efficient strategies were S1 followed by S2 and S5, and all had ICERs below $50,000 per QALY.
DISCUSSION
The These results differ significantly from previous analyses, due, in part, to our PPSV23 NBPP effectiveness assumptions, which were obtained through a Delphi panel process. For example, Smith et al. [9] also used a Delphi panel to estimate PCV13 effectiveness against NBPP; however, they did not report Delphi estimates for PPSV23 effectiveness against NBPP. Instead, the authors assumed the effectiveness of PPSV23 was zero in the basecase analysis [10] . Sensitivity analyses conducted as part of the Smith et al. [9] [11] analysis examined the impact of pneumococcal vaccines on all-cause pneumonia, rather than restricting the analysis to NBPP as we have done. Weycker et al. [11] used effectiveness assumptions similar to those used in Smith et al.
[9] for PPSV23, and they used pediatric data for pneumonia effectiveness assumptions for adult use of PCV13. Weycker et al. [11] did not explore whether their conclusions were influenced by their assumptions regarding the effectiveness of PPSV23 in preventing NBPP. Furthermore, most strategies considered by
Weycker et al. [11] assumed use of PCV13 in all adults age C50 years at model entry, which were inconsistent with ACIP recommendations.
We evaluated strategies with vaccination at age 50 for the lower risk population (details not reported) and found that these strategies were less economically efficient than the seven strategies explored in the analysis. As a result, we cannot compare our findings with their results.
CONCLUSION
The 2012 ACIP recommendation is the more economically efficient strategy comparing to 
